Allurion Q2 revenue $11.8M, sequential +25%; French regulator suspends Balloon sales; FY guidance lowered to $40-45M

ALLURION TECHNOLOGIES, INC.

2024-Q2 EPS reported $0.07 revenue$21,152,000

Q2 2024 revenue $11.8M, up 25% sequentially from Q1 but down from $13M in Q2 2023.
Operating loss improved to $9.3M from $13.3M in Q2 2023; record procedure volume >10,000 balloon placements for second straight quarter.
ANSM (French regulator) suspended Allurion Balloon sales; company withdrawing from France pending remediation plan on advertising and patient follow-up.
Full-year 2024 revenue guidance reduced to $40-45M from prior; procedure volume growth expected 10-15%.
Cash $19.3M at June 30; completed public offering in July 2024 for ~$22M gross proceeds.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.